The largest database of trusted experimental protocols

Lps escherichia coli serotype 0111 b4

Manufactured by Merck Group
Sourced in United States, Germany

LPS (Escherichia coli serotype 0111:B4) is a lab equipment product. It is a bacterial endotoxin derived from the cell wall of Escherichia coli. The core function of this product is to serve as a research tool for the study of inflammatory responses and immune system activation.

Automatically generated - may contain errors

54 protocols using lps escherichia coli serotype 0111 b4

1

Macrophage Polarization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
To activate the polarisation of macrophages, macrophages were stimulated by lipopolysaccharide (LPS).33 Briefly, RAW 264.7 macrophage cells (the National Experimental Cell Resource Sharing platform, Beijing, China) CM was prepared as follows: RAW 264.7 macrophage cells were seeded at 4 × 106 in 10‐cm tissue culture‐treated dishes. They were cultured with DMEM completed medium overnight before being treated with 1 μg/mL lipopolysaccharide (LPS, Escherichia coli serotype 0111: B4, Sigma‐Aldrich) for 24 h. Cell supernatant was discarded and RAW 264.7 macrophage cells were washed three times with phosphate buffer saline (PBS, HyClone, Thermo Scientific). After removing the supernatant, RAW 264.7 macrophage cells were cultured again in DMEM completed medium for another 24 h. The cell culture medium was then collected and centrifuged to remove cell debris. The remaining supernatant was designated as CM and utilized for subsequent experiments.
+ Open protocol
+ Expand
2

Autophagy Regulation in Bone Homeostasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
C57BL/6 mice were from The Jackson Laboratory and were maintained under specific pathogen-free conditions under protocols approved by Institutional Animal Care and Use Committees. Femurs from Atgflox/flox and Atgflox × CD11c-cre mice were a gift from David Lieb (Geisel School of Medicine, Dartmouth College, Hanover, NH). LPS (Escherichia coli sero-type 0111:B4) was from Sigma-Aldrich and used at 100 ng/ml. Etomoxir and 6-diazo-5-oxo-l-norleucine were purchased from Sigma-Aldrich. NOS inhibitor S-ethyl-isothiourea (SEITU, 500 μM) was purchased from Cayman Chemical. RAP (100 nM) was purchased from InvivoGen. KU 0063794 (KU, 100 nM) was purchased from Tocris Bioscience. 7-Aminoactinomycin D (7-AAD) and all Abs for FACS analysis were from BD Biosciences except for anti-CD40, which was purchased from eBioscience.
+ Open protocol
+ Expand
3

Neutrophil Recruitment Induced by LPS

Check if the same lab product or an alternative is used in the 5 most similar protocols
The recruitment of neutrophils to the lungs using LPS was as described previously [39 (link)]. In brief, mice were challenged with aerosolized PBS or 1 mg/mL LPS (Escherichia coli, serotype 0111:B4, Sigma-Aldrich Ltd. Poole, UK) for 30 min. 6 h post-challenge mice were euthanized and BAL collected. The lungs were collected and digested using collagenase as described previously [40 (link)]. Cells were cytospun onto glass slides and differential counts obtained by staining using Wright-Giemsa.
+ Open protocol
+ Expand
4

Monocyte Cytokine Responses to LPS and LTA

Check if the same lab product or an alternative is used in the 5 most similar protocols
An amount of 1 × 105 CD14+ cells in RPMI were seeded per well into 96-well cell culture plates and incubated for 24 h at 37 °C in either RPMI media alone, RPMI with 1 µg/mL lipopolysaccharide (LPS; Escherichia coli serotype 0111:B4, Sigma, St. Louis, MO, USA), or 10 µg/mL lipoteichoic acid (LTA; Staphylococcus aureus, Sigma, St. Louis, MO, USA). Culture conditions included 5% CO2. The timing of stimulation was based on prior studies indicating that 24 h stimulation was optimal for monocyte production of innate inflammatory cytokines. After incubation period was over, the plates were centrifuged at 2000 rpm for 10 min after which time supernatant was collected from each well and stored at −80 °C.
+ Open protocol
+ Expand
5

Mice LPS-Induced Sepsis Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were intraperitoneally injected with 15 mg/kg of LPS (Escherichia coli serotype 0111:B4; Sigma–Aldrich) as described elsewhere27 (link),32 (link). After LPS injection, the survival of the mice was monitored. Peritoneal cells and fluids were collected at 0, 3 and 6 hours after LPS injection, as described elsewhere32 (link).
+ Open protocol
+ Expand
6

Intradermal and Intrathecal Itch Induction

Check if the same lab product or an alternative is used in the 5 most similar protocols
We purchased compound 48/80, chloroquine, diphenylcyclopropenone (DCP), 2,4-dinitrofluorobenzene (DNFB), L-α-aminoadipate (L-AA), LPS (Escherichia coli serotype 0111:B4) from Sigma-Aldrich and LPS Rhodobacter sphaeroides (LPS-RS) from R&D Systems. We injected the pruritic agents (compound 48/80 and chloroquine) intradermally with a 28-Gauge needle in the nape (back of the neck, 50 μl) or cheek (10 μl). According to previous reports [7 (link);15 (link);19 (link);55 (link)], we also injected the following reagents intrathecally to target spinal cord cells: LPS-RS (20 μg) and L-AA (100 nmol) [70 (link)]. Intrathecal injection was performed by a lumbar puncture to deliver reagent into cerebral spinal fluid. A valid spinal puncture was confirmed by a brisk tail-flick after the needle entry into subarachnoid space [21 (link)]. We injected LPS or L-AA 24 hours before itch assay and injected LPS-RS 30 min prior to itch assay. Reagents were dissolved in sterile saline as vehicle if not specified.
+ Open protocol
+ Expand
7

Endotoxemia Induction in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were intraperitoneally (i.p.) injected with 1 mg/kg per body weight (b.w.) lipopolysaccharide (LPS, Escherichia coli, serotype 0111:B4; Sigma‐Aldrich, Saint Louis, MO, USA) in 0.9% saline (NaCl) to induce endotoxemia48 (link). Mice were subsequently subjected to sample collection or intravital imaging as detailed below. Some of their counterparts were untreated (healthy controls, 0 h).
+ Open protocol
+ Expand
8

HDAC 1-3 Silencing in RAW 264.7 Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to downregulate the expression of HDACs 1, 2 and 3, cells were subjected to HDAC 1–3 selective siRNAs as follows. One day prior to transfection, RAW 264.7 macrophages were seeded at 20,000 cells/cm2 to obtain identical cell density at the start of the experiment. siRNA transfection experiments were performed in a 12-well plate upon complexing 50 nM siRNA with 3.5 μl Lipofectamine® 2000 (LF2K, Life technologies) according to the manufacturer’s protocol. After 24 h RAW 264.7 macrophages were washed twice with ice-cold PBS and harvested for RNA isolation or Western blotting. Where indicated, cells were stimulated with 10 ng/ml lipopolysaccharide (LPS, Escherichia coli, serotype 0111:B4; Sigma–Aldrich, Zwijndrecht, The Netherlands) and 10 ng/ml interferon gamma (IFNγ, #315-05; PeproTech, Hamburg, Germany) for the last 4 h of the experiment. The following siRNAs were used: mouse HDAC 1 (s119559), HDAC 2 (s67417), HDAC 3 (s67421) and Negative Control siRNA (4390843). All siRNAs used were Silencer® Select Pre-Designed & Validated siRNAs purchased from Ambion® by Life Technologies.
+ Open protocol
+ Expand
9

Evaluating IL-35-ADSC Therapy for LPS-Induced ALI

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eighteen mice (8–10 weeks) were anesthetized via isoflurane inhalation in a small sealed box and randomly received 8 × 105 IL-35-ADSCs (in 200-μL sterile normal saline (NS)), 8 × 105 GFP-ADSCs (in 200-μL NS) or isovolumetric NS via tail vein injection (6 mice per group) 7 days before LPS administration. Another 6 mice received nothing and were used as the sham group. The LPS-induced ALI model was constructed in mice in accordance with previous reports (Zhang et al. 2018b (link)). All 18 mice received intratracheal (i.t.) instillation of a single dose of 100-μg LPS (Escherichia coli serotype 0111: B4, Sigma-Aldrich) in 50-μL NS. Mice in the sham group were administered 50-μL NS instead of LPS. The four groups were named Sham, saline + LPS (negative control), GFP-ADSCs + LPS (positive control) and IL-35-ADSCs + LPS, respectively. All mice were anesthetized through intraperitoneal injection of chloral hydrate (330 mg/kg), and bronchoalveolar lavage fluid (BALF) and abdominal aortic blood were collected 24 h post LPS exposure. Then, the mice were killed via cervical dislocation, and lung, spleen and peripheral blood samples were harvested. The weight of the mice was recorded at different time points. The wet/dry weight ratio of the right lung was also calculated.
+ Open protocol
+ Expand
10

Quantifying Microglia Cytokine Release

Check if the same lab product or an alternative is used in the 5 most similar protocols
IL-1 β and TNF-α levels were measured in the supernatant of LPS-stimulated or unstimulated microglia cultures in 96-well plates. LPS (Escherichia coli serotype 0111: B4; Sigma-Aldrich) was applied at a concentration of 1 µg/ml. After 6- or 24-h incubation for stimulation of TNF-α or IL-1 β release, respectively (per methods described by Kowalski et al., 2003 (link); Kowalski et al., 2004 (link)), the culture medium was harvested and centrifuged (2,000 × g, 5 min). Cytokine quantification was performed using rat ELISA kits (R&D Systems, USA) following the manufacturer's instructions. Absorbance was measured at 450 nm using the plate reader Mulitskan RC (Labsystems). Intra-assay precision, as measured using coefficient of variation for TNF-α, IL-1β was 7.4% and 8.7%, respectively. Sensitivity of determination for both TNF-α and IL-1β was 5 pg/ml. The data were obtained from three independent experiments (i.e., three independent microglia cultures established from pups of three different dams in each group, for a total of n = 9 per group).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!